TY - JOUR
T1 - Six-Month Outcomes in the Long-Term Outcomes after the Multisystem Inflammatory Syndrome in Children Study
AU - The MUSIC Study Investigators
AU - Truong, Dongngan T.
AU - Trachtenberg, Felicia L.
AU - Hu, Chenwei
AU - Pearson, Gail D.
AU - Friedman, Kevin
AU - Sabati, Arash A.
AU - Dionne, Audrey
AU - Oster, Matthew E.
AU - Anderson, Brett R.
AU - Block, Joseph
AU - Bradford, Tamara T.
AU - Campbell, M. Jay
AU - D'Addese, Laura
AU - Dummer, Kirsten B.
AU - Elias, Matthew D.
AU - Forsha, Daniel
AU - Garuba, Olukayode D.
AU - Hasbani, Keren
AU - Hayes, Kerri
AU - Hebson, Camden
AU - Jone, Pei Ni
AU - Krishnan, Anita
AU - Lang, Sean
AU - McCrindle, Brian W.
AU - McHugh, Kimberly E.
AU - Mitchell, Elizabeth C.
AU - Morrison, Tonia
AU - Muniz, Juan Carlos
AU - Payne, R. Mark
AU - Portman, Michael A.
AU - Russell, Mark W.
AU - Sanil, Yamuna
AU - Shakti, Divya
AU - Sharma, Kavita
AU - Shea, J. Ryan
AU - Sykes, Michelle
AU - Shekerdemian, Lara S.
AU - Szmuszkovicz, Jacqueline
AU - Thacker, Deepika
AU - Newburger, Jane W.
N1 - Publisher Copyright:
© 2025 American Medical Association. All rights reserved, including those for text and data mining, AI training, and similar technologies.
PY - 2025/3/1
Y1 - 2025/3/1
N2 - IMPORTANCE: Multisystem inflammatory syndrome in children (MIS-C) is a life-threatening complication of COVID-19 infection. Data on midterm outcomes are limited.OBJECTIVE: To characterize the frequency and time course of cardiac dysfunction (left ventricular ejection fraction [LVEF] <55%), coronary artery aneurysms (z score ≥2.5), and noncardiac involvement through 6 months after MIS-C.DESIGN, SETTING, AND PARTICIPANTS: This cohort study enrolled participants between March 2020 and January 2022 with a follow-up period of 2 years. Participants were recruited from 32 North American pediatric hospitals, and all participants met the 2020 Centers for Disease Control and Prevention case definition of MIS-C.EXPOSURE: MIS-C after COVID-19 infection.MAIN OUTCOMES AND MEASURES: Outcomes included echocardiography core laboratory (ECL) assessments of LVEF and maximum coronary artery z scores (zMax); data collection on cardiac and noncardiac sequelae during hospitalization and at 2 weeks, 6 weeks, and 6 months after discharge; and age-appropriate Patient-Reported Outcomes Measurement Information Systems (PROMIS) Global Health Instruments at follow-up. Descriptive statistics, linear regression models, and Kaplan-Meier analysis were used.RESULTS: Of 1204 participants (median [IQR] age, 9.1 [5.6-12.7] years; 724 male [60.1%]), 325 self-identified with non-Hispanic Black race (27.0%) and 324 with Hispanic ethnicity (26.9%). A total of 548 of 1195 participants (45.9%) required vasoactive support, 17 of 1195 (1.4%) required extracorporeal membrane oxygenation, and 3 (0.3%) died during hospitalization. Of participants with echocardiograms reviewed by the ECL (n = 349 due to budget constraints), 131 of 322 (42.3%) had LVEF less than 55% during hospitalization; of those with follow-up, all but 1 normalized by 6 months. Black race (vs other/unknown race), higher C-reactive protein level, and abnormal troponin level were associated with lowest LVEF (estimate [SE], -3.09 [0.98]; R2 = 0.14; P =.002). Fifteen participants had coronary artery z scores of 2.5 or greater at any time point; 1 participant had a large/giant aneurysm. Of the 13 participants with z scores of 2.5 or greater during hospitalization, 12 (92.3%) had normalized by 6 months. Return to greater than 90% of pre-MIS-C health status (energy, sleep, appetite, cognition, and mood) was reported by 711 of 824 participants (86.3%) at 2 weeks, increasing to 548 of 576 (95.1%) at 6 months. Fatigue was the most common symptom reported at 2 weeks (141 of 889 [15.9%]), falling to 3.4% (22 of 638) by 6 months. PROMIS Global Health parent/guardian proxy median T scores for fatigue, global health, and pain interference improved significantly from 2 weeks to 6 months (fatigue, 56.1 vs 48.9; global health, 48.8 vs 51.3; pain interference, 53.0 vs 43.3; P < .001) and by the 6-week visit were at least equivalent to prepandemic population norms.CONCLUSIONS AND RELEVANCE: Results of this cohort study suggest that although children and young adults with MIS-C can have severe disease during the acute phase, most recovered quickly and had a reassuring midterm prognosis.
AB - IMPORTANCE: Multisystem inflammatory syndrome in children (MIS-C) is a life-threatening complication of COVID-19 infection. Data on midterm outcomes are limited.OBJECTIVE: To characterize the frequency and time course of cardiac dysfunction (left ventricular ejection fraction [LVEF] <55%), coronary artery aneurysms (z score ≥2.5), and noncardiac involvement through 6 months after MIS-C.DESIGN, SETTING, AND PARTICIPANTS: This cohort study enrolled participants between March 2020 and January 2022 with a follow-up period of 2 years. Participants were recruited from 32 North American pediatric hospitals, and all participants met the 2020 Centers for Disease Control and Prevention case definition of MIS-C.EXPOSURE: MIS-C after COVID-19 infection.MAIN OUTCOMES AND MEASURES: Outcomes included echocardiography core laboratory (ECL) assessments of LVEF and maximum coronary artery z scores (zMax); data collection on cardiac and noncardiac sequelae during hospitalization and at 2 weeks, 6 weeks, and 6 months after discharge; and age-appropriate Patient-Reported Outcomes Measurement Information Systems (PROMIS) Global Health Instruments at follow-up. Descriptive statistics, linear regression models, and Kaplan-Meier analysis were used.RESULTS: Of 1204 participants (median [IQR] age, 9.1 [5.6-12.7] years; 724 male [60.1%]), 325 self-identified with non-Hispanic Black race (27.0%) and 324 with Hispanic ethnicity (26.9%). A total of 548 of 1195 participants (45.9%) required vasoactive support, 17 of 1195 (1.4%) required extracorporeal membrane oxygenation, and 3 (0.3%) died during hospitalization. Of participants with echocardiograms reviewed by the ECL (n = 349 due to budget constraints), 131 of 322 (42.3%) had LVEF less than 55% during hospitalization; of those with follow-up, all but 1 normalized by 6 months. Black race (vs other/unknown race), higher C-reactive protein level, and abnormal troponin level were associated with lowest LVEF (estimate [SE], -3.09 [0.98]; R2 = 0.14; P =.002). Fifteen participants had coronary artery z scores of 2.5 or greater at any time point; 1 participant had a large/giant aneurysm. Of the 13 participants with z scores of 2.5 or greater during hospitalization, 12 (92.3%) had normalized by 6 months. Return to greater than 90% of pre-MIS-C health status (energy, sleep, appetite, cognition, and mood) was reported by 711 of 824 participants (86.3%) at 2 weeks, increasing to 548 of 576 (95.1%) at 6 months. Fatigue was the most common symptom reported at 2 weeks (141 of 889 [15.9%]), falling to 3.4% (22 of 638) by 6 months. PROMIS Global Health parent/guardian proxy median T scores for fatigue, global health, and pain interference improved significantly from 2 weeks to 6 months (fatigue, 56.1 vs 48.9; global health, 48.8 vs 51.3; pain interference, 53.0 vs 43.3; P < .001) and by the 6-week visit were at least equivalent to prepandemic population norms.CONCLUSIONS AND RELEVANCE: Results of this cohort study suggest that although children and young adults with MIS-C can have severe disease during the acute phase, most recovered quickly and had a reassuring midterm prognosis.
KW - Adolescent
KW - COVID-19/complications
KW - Child
KW - Child, Preschool
KW - Cohort Studies
KW - Coronary Aneurysm/epidemiology
KW - Echocardiography
KW - Female
KW - Follow-Up Studies
KW - Humans
KW - Male
KW - Stroke Volume/physiology
KW - Systemic Inflammatory Response Syndrome/epidemiology
UR - https://www.scopus.com/pages/publications/85216404137
U2 - 10.1001/jamapediatrics.2024.5466
DO - 10.1001/jamapediatrics.2024.5466
M3 - Article
C2 - 39804656
AN - SCOPUS:85216404137
SN - 2168-6203
VL - 179
SP - 293
EP - 301
JO - JAMA Pediatrics
JF - JAMA Pediatrics
IS - 3
ER -